Report #2854807

Received Aug 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Jun 12, 2025
Onset: Jun 12, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	946062	IM / RA

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Receive Engerix B and then Heplisav-B; Initial report received on 12-Aug-2025. A pharmacist reported that a 36-year-old female received the first dose of ENGERIX-B for (hepatitis B vaccine) for hepatitis B immunization, then received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization. No medical history or concomitant medications were reported. In May- 2023, the patient received dose 1 of a hepatitis B vaccine [ENGERIX-B (lot #, expiration date, NDC #, route, and site not available). On 12-Jun-2025, 745 days after having been vaccinated with ENGERIX-B, the patient received a dose of a hepatitis b vaccine [HEPLISAV-B (lot # 946062, expiration date 18-May-2027, NDC # 43528-0003-05)] intramuscularly in the right arm. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Other medications

Engerix b